Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis.

Trial Profile

Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Memantine; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms MEDALS
  • Most Recent Events

    • 24 Mar 2012 Additional lead trial investigator (Jorge Matias-Guiu Guia) identified as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Planned number of patients changed from 60 to 140 as reported by European Clinical Trials Database record.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top